These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19887460)

  • 1. Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B.
    Cornely OA; Maertens J; Bresnik M; Ullmann AJ; Ebrahimi R; Herbrecht R
    J Antimicrob Chemother; 2010 Jan; 65(1):114-7. PubMed ID: 19887460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
    Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
    Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
    Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
    Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Dellow E; Herbrecht R; Donnelly JP
    Mycoses; 2011 Sep; 54(5):e449-55. PubMed ID: 21039936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of voriconazole in the treatment of central nervous system blastomycosis.
    Ta M; Flowers SA; Rogers PD
    Ann Pharmacother; 2009 Oct; 43(10):1696-700. PubMed ID: 19724015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
    Cordonnier C; Bresnik M; Ebrahimi R
    Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
    Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
    Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection.
    Bodhe PV; Kotwani RN; Kirodian BG; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 2002 May; 50(5):662-70. PubMed ID: 12186120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
    Le A; Farmakiotis D; Tarrand JJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of amphotericin B in the treatment of invasive fungal infections.
    Klepser M
    J Crit Care; 2011 Apr; 26(2):225.e1-10. PubMed ID: 20951541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of drug and food interactions with azole antifungal agents in transplant recipients.
    Dodds-Ashley E
    Pharmacotherapy; 2010 Aug; 30(8):842-54. PubMed ID: 20653361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal amphotericin B in critically ill paediatric patients.
    Sideri G; Falagas ME; Grigoriou M; Vouloumanou EK; Papadatos JH; Lebessi E; Kafetzis DA
    J Clin Pharm Ther; 2012 Jun; 37(3):291-5. PubMed ID: 21777406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of systemic fungal infections in older patients: achieving optimal outcomes.
    Kauffman CA; Hedderwick SA
    Drugs Aging; 2001; 18(5):313-23. PubMed ID: 11392440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of the use of liposomal amphotericin B].
    González Martínez M; Mariño Martínez C; Baldominos Utrilla G; Fernández Martínez MN
    Rev Iberoam Micol; 2014; 31(2):109-13. PubMed ID: 23711815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antifungal therapy: where are we now, and where are we going?
    Marr K
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.